Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Exagen (XGN) Equity Average (2018 - 2026)

Exagen filings provide 9 years of Equity Average readings, the most recent being $15.9 million for Q1 2026.

  • On a quarterly basis, Equity Average rose 99.97% to $15.9 million in Q1 2026 year-over-year; TTM through Mar 2026 was $15.9 million, a 99.97% increase, with the full-year FY2025 number at $13.5 million, down 16.27% from a year prior.
  • Equity Average hit $15.9 million in Q1 2026 for Exagen, down from $17.8 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $80.5 million in Q1 2022 to a low of $8.0 million in Q1 2025.
  • Median Equity Average over the past 5 years was $21.3 million (2024), compared with a mean of $31.1 million.
  • Biggest five-year swings in Equity Average: plummeted 62.65% in 2025 and later surged 99.97% in 2026.
  • Exagen's Equity Average stood at $49.3 million in 2022, then plummeted by 49.11% to $25.1 million in 2023, then tumbled by 55.36% to $11.2 million in 2024, then surged by 58.81% to $17.8 million in 2025, then decreased by 10.41% to $15.9 million in 2026.
  • The last three reported values for Equity Average were $15.9 million (Q1 2026), $17.8 million (Q4 2025), and $19.6 million (Q3 2025) per Business Quant data.